John L. Berk MD
Professor, Pulmonary, Allergy, Sleep & Critical Care Medicine
Graduate Faculty (Primary Mentor of Grad Students)
72 E. Concord Street | (617) 358-4774jberk@bu.edu
john.berk@bmc.org
Sections
Pulmonary, Allergy, Sleep & Critical Care Medicine
Centers
Pulmonary Center
Amyloidosis Center
Evans Center for Interdisciplinary Biomedical Research
Biography
Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.
Education
MD, Case Western Reserve University
Biology, BA, Wesleyan University
Publications
Luigetti M, Quan D, Berk JL, Conceição I, Misumi Y, Chao CC, Bender S, Aldinc E, Vest J, Adams D. Impact of Baseline Neuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study. Neurol Ther. 2024 Mar 21. PMID: 38512694.
Published on 2/6/2024Garcia-Pavia P, Grogan M, Kale P, Berk JL, Maurer MS, Conceição I, Di Carli M, Solomon SD, Chen C, Yureneva E, Vest J, Gillmore JD. Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. Eur J Heart Fail. 2024 Feb; 26(2):397-410. PMID: 38321786.
Published on 12/11/2023Lau KHV, Prokaeva T, Zheng L, Doros G, Kaku MC, Spencer B, Berk J, Sanchorawala V. Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis. Amyloid. 2023 Dec 11; 1-3. PMID: 38073425.
Published on 12/7/2023Masri A, Maurer MS, Claggett BL, Kulac I, Waddington Cruz M, Conceição I, Weiler M, Berk JL, Gertz M, Gillmore JD, Rush S, Chen J, Zhou W, Kwoh J, Duran JM, Tsimikas S, Solomon SD. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2023 Dec 07. PMID: 38065307.
Published on 10/26/2023Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD. Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. N Engl J Med. 2023 Oct 26; 389(17):1553-1565. PMID: 37888916.
Published on 10/17/2023Coelho T, Marques W, Dasgupta NR, Chao CC, Parman Y, França MC, Guo YC, Wixner J, Ro LS, Calandra CR, Kowacs PA, Berk JL, Obici L, Barroso FA, Weiler M, Conceição I, Jung SW, Buchele G, Brambatti M, Chen J, Hughes SG, Schneider E, Viney NJ, Masri A, Gertz MR, Ando Y, Gillmore JD, Khella S, Dyck PJB, Waddington Cruz M. Eplontersen for Hereditary Transthyretin Amyloidosis With Polyneuropathy. JAMA. 2023 Oct 17; 330(15):1448-1458. PMID: 37768671.
Published on 7/31/2023Obici L, Ajroud-Driss S, Lin KP, Berk JL, Gillmore JD, Kale P, Koike H, Danese D, Aldinc E, Chen C, Vest J, Adams D. Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy. Neurol Ther. 2023 Oct; 12(5):1759-1775. PMID: 37523143.
Published on 12/16/2022Coelho T, Waddington Cruz M, Chao CC, Parman Y, Wixner J, Weiler M, Barroso FA, Dasgupta NR, Jung SW, Schneider E, Viney NJ, Dyck PJB, Ando Y, Gillmore JD, Khella S, Gertz MA, Obici L, Berk JL. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen. Neurol Ther. 2023 Feb; 12(1):267-287. PMID: 36525140.
Published on 11/29/2022Tsai FJ, Nelson LT, Kline GM, Jäger M, Berk JL, Sekijima Y, Powers ET, Kelly JW. Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange. Amyloid. 2023 Jun; 30(2):220-224. PMID: 36444793.
Published on 11/16/2022Brannagan TH, Berk JL, Gillmore JD, Maurer MS, Waddington-Cruz M, Fontana M, Masri A, Obici L, Brambatti M, Baker BF, Hannan LA, Buchele G, Viney NJ, Coelho T, Nativi-Nicolau J. Liver-directed drugs for transthyretin-mediated amyloidosis. J Peripher Nerv Syst. 2022 Dec; 27(4):228-237. PMID: 36345805.
Media Mentions
Published on 9/13/2022
Patisiran beneficial in ATTR amyloidosis with cardiomyopathy
Published on 9/8/2022
Alnylam details anticipated results from heart disease drug trial`
Published on 8/3/2022
Alnylam’s stock soars by nearly 50 percent on trial results for heart drug
Published on 6/26/2021
Intellia, with first results, delivers a 'landmark' for CRISPR gene editing
Published on 6/26/2021
Published on 3/12/2021
Published on 9/22/2020
Trial Data Provide Proof-of-concept for CRX-1008 as Leptomeningeal FAP Treatment
Published on 8/27/2018
Eyeing Approval, Pfizer Touts Tafamidis Data but Omits Key Details
Published on 8/3/2018
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
View full list of 9 media mentions.